This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

The Effect of Eszopiclone in Patients With Insomnia and Coexisting Rheumatoid Arthritis: A Pilot Study

Thomas Roth, PhD; Janet M. Price, MD; David A. Amato, PhD; Robert P. Rubens, MD; James M. Roach, MD; and Thomas J. Schnitzer, MD

Published: December 17, 2009

Article Abstract

Objective: To evaluate the efficacy and safety of eszopiclone 3 mg, a nonbenzodiazepine medication/hypnotic indicated for the treatment of insomnia with comorbid rheumatoid arthritis (RA).

Method: This multicenter, double-blind, placebo-controlled pilot study was conducted in 153 patients aged 25-64 years with American College of Rheumatology-defined RA who met DSM-IV criteria for insomnia. The data were collected from February to November of 2004. Patients were randomly assigned to either eszopiclone or placebo nightly for 4 weeks, followed by a 2-week placebo run out. Efficacy was evaluated using patient reports of sleep (wake time after sleep onset [WASO], sleep latency [SL], and total sleep time [TST]), daytime function, pain, and RA assessments. Insomnia severity was evaluated using the Insomnia Severity Index. Safety was also evaluated.

Results: Eszopiclone significantly improved all patient-reported sleep measures (WASO, SL, and TST), sleep quality, depth of sleep, and daytime function (P P =.03). Eszopiclone was significantly better than placebo on some RA-associated pain measures: (1) overall (P =.05), pain (P =.006), and pain and other symptoms (P =.02) scores of the Arthritis Self-Efficacy Scale, (2) tender joint counts (P =.03) and pain severity scores (P =.023), (3) the activities domain of the Health Assessment Questionnaire-Disability Index (P =.04), and (4) the role physical (P =.03) and bodily pain (P =.01) scales of the 36-item Medical Outcomes Study Short-Form General Health Survey. The most commonly reported adverse events with eszopiclone were unpleasant taste and transient increases in RA symptoms

Conclusions: In this pilot study of patients with insomnia comorbid with RA, eszopiclone 3 mg improved all assessed sleep and daytime function measures over the treatment period, as well as some measures of RA-associated pain, disability, and quality of life

Trial Registration: Identifier: NCT00367965

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 11

Quick Links: